Status:

UNKNOWN

Novel Quantitative Magnetic Resonance Imaging (MRI) Measures in the Assessment and Follow-up of Patients With Pulmonary Hypertension (PH)

Lead Sponsor:

Royal Brompton & Harefield NHS Foundation Trust

Conditions:

Pulmonary Hypertension

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

A prospective study of the use of two novel MRI techniques (oxygen-enhanced and fourier decomposition MRI) in the initial diagnosis and follow-up of patients with Pulmonary Hypertension. The investiga...

Eligibility Criteria

Inclusion

  • Confirmed diagnosis of Pulmonary Hypertension.
  • Age 18 and over.

Exclusion

  • Standard contra-indications to MRI (as per NHS MRI safety questionnaire).
  • Not medically fit for transfer to MRI.
  • Patient judged inappropriate for involvement in study by clinical team e.g. secondary to emotional burden of recent diagnosis.

Key Trial Info

Start Date :

November 19 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2021

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT04088279

Start Date

November 19 2018

End Date

June 1 2021

Last Update

September 12 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Royal Brompton Hospital

London, United Kingdom

Novel Quantitative Magnetic Resonance Imaging (MRI) Measures in the Assessment and Follow-up of Patients With Pulmonary Hypertension (PH) | DecenTrialz